Table 3.
Univariate Cox regression analyses (n = 82).
| HR (CI 95%) | p-Value | |
|---|---|---|
| Gender | 0.611 | |
| Female | 1 | |
| Male | 1.13 (0.70 to 1.83) | |
| Age (years) | 0.838 | |
| <60 | 1 | |
| ≥60 | 1.05 (0.65 to 1.69) | |
| CA19.9 values at diagnosis (kU/L) | 0.990 | |
| <200 | 1 | |
| ≥200 | 0.99 (0.61 to 1.63) | |
| Primary Site | 0.851 | |
| Head/uncus/isthmus | 1 | |
| Body/tail | 1.05 (0.63 to 1.76) | |
| Tumour diameter (mm) | 0.776 | |
| <40 | 1 | |
| ≥40 | 0.93 (0.58 to 1.50) | |
| Staging TNM 8th ed. | 0.874 | |
| IB | 1 | |
| II A/B | 1.08 (0.46 to 2.52) | |
| III | 0.93 (0.44 to 1.97) | |
| Resection status | 0.277 | |
| Borderline | 1 | |
| Locally advanced | 0.77 (0.47 to 1.24) | |
| Number of induction CT cycles | 0.001 | |
| 0–3 | 1 | |
| 4–8 | 0.47 (0.27 to 0.81) | |
| >8 | 0.23 (0.09 to 0.54) | |
| Time of induction (months) | 0.005 | |
| <2 | 1 | |
| ≥2 & <4 | 0.46 (0.26 to 0.81) | |
| ≥4 | 0.38 (0.20 to 0.72) | |
| Type of induction CT | 0.025 | |
| None | 1 | |
| Gem-based (except Gem/Np) | 0.69 (0.31 to 1.51) | |
| mFFX/Gem-Np | 0.42 (0.20 to 0.84) | |
| Type of Radiotherapy | <0.001 | |
| CRT | 1 | |
| iHD-SBRT | 0.39 (0.24 to 0.64) | |
| Oncological resection | 0.009 | |
| No | 1 | |
| Yes | 0.47 (0.27 to 0.83) |
iHD-SBRT = isotoxic high-dose stereotactic body radiation therapy; CRT = chemoradiotherapy; CT = chemotherapy; mFFX = modified FOLFIRINOX; Gem-Np = gemcitabine/nab-paclitaxel, Gem = gemcitabine; HR = hazard ratio.